{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:50:09Z","timestamp":1789973409054,"version":"4.0.1"},"reference-count":149,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.critrevonc.2014.09.001","type":"journal-article","created":{"date-parts":[[2014,9,28]],"date-time":"2014-09-28T20:37:08Z","timestamp":1411936628000},"page":"75-89","source":"Crossref","is-referenced-by-count":44,"title":["The genetic basis of mast cell activation disease - looking through a glass darkly"],"prefix":"10.1016","volume":"93","author":[{"given":"Gerhard J.","family":"Molderings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2014.09.001_bib0005","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/stem.523","article-title":"Adipose tissue as a dedicated reservoir of functional mast cell progenitors","volume":"28","author":"Poglio","year":"2010","journal-title":"Stem Cells"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fimmu.2012.00120","article-title":"Mast cell: an emerging partner in immune interaction","volume":"3","author":"Gri","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-4-10","article-title":"Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options","volume":"4","author":"Molderings","year":"2011","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MAJ.0b013e31821d41dd","article-title":"Polycythemia from mast cell activation syndrome: lessons learned","volume":"342","author":"Afrin","year":"2011","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5315\/wjh.v3.i1","article-title":"A concise, practical guide to diagnostic assessment for mast cell activation disease","volume":"3","author":"Afrin","year":"2014","journal-title":"World J Hematol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0035","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0040","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0045","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/00365520701245744","article-title":"Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder","volume":"42","author":"Molderings","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0050","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00251-010-0474-8","article-title":"Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects","volume":"62","author":"Molderings","year":"2010","journal-title":"Immunogenetics"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2011.04.037","article-title":"Mast cell activation syndrome: A\u00a0newly recognized disorder with systemic clinical manifestations","volume":"128","author":"Hamilton","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0060","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1038\/leu.2013.227","article-title":"Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0065","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","article-title":"Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal","volume":"25","author":"Valent","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0070","doi-asserted-by":"crossref","first-page":"e2266","DOI":"10.1371\/journal.pone.0002266","article-title":"Case-control cohort study of patients\u2019 perceptions of disability in mastocytosis","volume":"3","author":"Hermine","year":"2008","journal-title":"PLoS ONE."},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0075","doi-asserted-by":"crossref","first-page":"e1906","DOI":"10.1371\/journal.pone.0001906","article-title":"Phenotypic and genotypic characteristics of mastocytosis according to the age of onset","volume":"3","author":"Lanternier","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0080","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0085","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0090","doi-asserted-by":"crossref","unstructured":"Merante S, Magliacane D, Neri I, Pascutto C, Zanotti R, Forer I, et al. The New Italian Mastocytosis Registry. 53rd ASH Annual Meeting and Exposition 2010, Poster 3805, http:\/\/ash.confex.com\/ash\/2010\/webprogram\/Paper28567.html.","DOI":"10.1182\/blood.V116.21.3805.3805"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0095","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2567.2012.03627.x","article-title":"Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics","volume":"137","author":"Haenisch","year":"2012","journal-title":"Immunology"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0100","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jaci.2012.10.015","article-title":"Prevalence of indolent systemic mastocytosis in a Dutch region","volume":"131","author":"van Doormaal","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0105","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0110","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0115","doi-asserted-by":"crossref","first-page":"e76241","DOI":"10.1371\/journal.pone.0076241","article-title":"Familial occurrence of systemic mast cell activation disease","volume":"8","author":"Molderings","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/205873920601900102","article-title":"Fibromyalgia--new concepts of pathogenesis and treatment","volume":"19","author":"Lucas","year":"2006","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0125","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s10067-010-1474-7","article-title":"Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients","volume":"29","author":"Blanco","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0130","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3109\/s10165-012-0679-9","article-title":"A case of fibromyalgia syndrome with anaphylaxis induced by intradermal injection of purified protein derivative","volume":"23","author":"Maeshima","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0135","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00365520410009410","article-title":"Pathogenesis of issitable bowel syndrome: The mast cell connection","volume":"40","author":"Santos","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0140","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/gut.2010.213108","article-title":"The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome","volume":"59","author":"Klooker","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0145","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0029-1245707","article-title":"Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome","volume":"49","author":"Frieling","year":"2011","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0150","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1055\/s-0031-1273323","article-title":"Irritable bowel syndrom--a misnomer?","volume":"49","author":"Frieling","year":"2011","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0155","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c- kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0160","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-kit catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0165","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0170","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000085563","article-title":"Clonality and molecular pathogenesis of mastocytosis","volume":"114","author":"Akin","year":"2005","journal-title":"Acta haematol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0180","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D(816)V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0185","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2141.2007.06619.x","article-title":"REMA. Recent advances in the understanding of mastocytosis: the role of KIT mutations","volume":"138","author":"Orfao","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0190","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0195","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.2012.01789.x","article-title":"on behalf of the Mastocytosis Centre Odense University Hospital (MastOUH). Circulating KIT D816V mutation positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis","volume":"89","author":"Kristensen","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0200","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/leu.2011.293","article-title":"An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis","volume":"26","author":"Teodosio","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0205","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.bbrc.2005.09.150","article-title":"Structure and regulation of Kit protein-tyrosine kinase - The stem cell factor receptor","volume":"338","author":"Roskoski","year":"2005","journal-title":"Bichem Biophys Res Commun"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0210","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1541-7786.MCR-09-0138","article-title":"The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment","volume":"7","author":"Bougherara","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0215","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood-2010-04-279752","article-title":"New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases","volume":"116","author":"Toffalini","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0220","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-065X.2008.00742.x","article-title":"The tyrosine kinase network regulating mast cell activation","volume":"228","author":"Gilfillan","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0225","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.4049\/jimmunol.180.8.5466","article-title":"Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens","volume":"180","author":"Mayerhofer","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0230","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.10.020","article-title":"Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes","volume":"125","author":"Teodosio","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0235","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2009-06-226027","article-title":"Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations","volume":"116","author":"Yang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0240","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jaci.2013.02.019","article-title":"Mastocytosis Centre Odense University Hospital (MastOUH). KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis","volume":"132","author":"Broesby-Olsen","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0245","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.leukres.2008.06.011","article-title":"c-Kit expression in human normal and malignant stem cells prognostic and therapeutic implications","volume":"33","author":"Hassan","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0250","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.molonc.2010.04.008","article-title":"High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V","volume":"4","author":"Fritsche-Polanz","year":"2010","journal-title":"Mol Oncol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0255","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/path.2677","article-title":"Variable presence of KIT(D816V) in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)","volume":"220","author":"Sotlar","year":"2010","journal-title":"J Pathol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0260","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/jcp.2009.067876","article-title":"KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation","volume":"62","author":"McClintock-Treep","year":"2009","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0265","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0270","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","article-title":"In aggressive forms of mastocytosis TET2 loss cooperates with c-KITD816V to transform mast cells","volume":"120","author":"Soucie","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0275","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","article-title":"Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2","volume":"468","author":"Ko","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0280","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fonc.2013.00169","article-title":"The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms","volume":"3","author":"Rakheja","year":"2013","journal-title":"Front Oncol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0285","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molmed.2010.07.002","article-title":"IDH mutations in glioma and acute myeloid leukemia","volume":"16","author":"Dang","year":"2010","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0290","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0295","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0300","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3324\/haematol.2013.095133","article-title":"SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes","volume":"99","author":"Hanssens","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0305","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.exphem.2013.05.005","article-title":"KIT GNNK splice variants: Expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells","volume":"41","author":"Chan","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0310","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ng.2709","article-title":"A new player SETs in myeloid malignancy","volume":"45","author":"Trimarchi","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0315","doi-asserted-by":"crossref","first-page":"e85362","DOI":"10.1371\/journal.pone.0085362","article-title":"ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases","volume":"9","author":"Damaj","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0320","first-page":"e43090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A","volume":"7","author":"Traina","year":"2012","journal-title":"ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0325","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0330","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0165-4608(99)00256-3","article-title":"Cytogenetic studies in patients with mastocytosis","volume":"120","author":"Swolin","year":"2000","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0335","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/ajh.10147","article-title":"Trisomies 8 and 9 not detected with fish in patients with mastocytosis","volume":"70","author":"Swolin","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0340","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s002770000271","article-title":"Complex karyotype and absence of mutation in the c- kit receptor in aggressive mastocytosis presenting with pelvic osteolysis, eosinophilia and brain damage","volume":"80","author":"Jost","year":"2001","journal-title":"Ann Hematol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0345","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10428190400010775","article-title":"Mastocytosis: Pathology, genetics, and current options for therapy","volume":"46","author":"Valent","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0350","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.leukres.2013.04.020","article-title":"The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients","volume":"37","author":"Won","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0355","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.23380","article-title":"Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components","volume":"88","author":"Wang","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0360","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Georgin-Lavialle","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0365","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood.V97.11.3559","article-title":"Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells","volume":"97","author":"Ning","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0370","doi-asserted-by":"crossref","first-page":"25756","DOI":"10.1074\/jbc.M202575200","volume":"277","author":"Yang","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0375","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1007\/s12032-012-0261-5","article-title":"Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm","volume":"29","author":"G\u00fclen","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0380","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3343\/alm.2013.33.2.125","article-title":"A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation","volume":"33","author":"Bae","year":"2013","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0385","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood-2009-10-249979","article-title":"WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults","volume":"115","author":"Pardanani","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0390","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11882-012-0326-8","article-title":"Immunology and clinical manifestations of non-clonal mast cell activation syndrome","volume":"13","author":"Cardet","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0395","doi-asserted-by":"crossref","first-page":"e34977","DOI":"10.1371\/journal.pone.0034977","article-title":"The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1\u03b2 and IL-18 production","volume":"7","author":"Verma","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0400","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.immuni.2012.04.013","article-title":"Critical role for mast cells in interleukin-1\u03b2-driven skin inflammation associated with an activating mutation in the nlrp3 protein","volume":"37","author":"Nakamura","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0405","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00251-014-0768-3","article-title":"Evidence for contribution of epigenetic mechanisms in the pathogenesis of systemic mast cell activation disease","volume":"66","author":"Haenisch","year":"2014","journal-title":"Immunogenetics"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0410","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood-2004-07-2639","article-title":"Rapid and large amount of autocrine IL-3 production is responsible for mast cell survival by IgE in the absence of antigen","volume":"105","author":"Kohno","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0415","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2008-08-175190","article-title":"Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs","volume":"114","author":"Aichberger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0420","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1038\/cddis.2010.20","article-title":"Pro-apoptotic Bax is the major and Bak an auxiliary effector in cytokine deprivation-induced mast cell apoptosis","volume":"1","author":"Karlberg","year":"2010","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0425","doi-asserted-by":"crossref","first-page":"S300","DOI":"10.2310\/6650.2005.00006.266","article-title":"Familial cases of mast cell diseases [abstract]","volume":"53","author":"Burks","year":"2005","journal-title":"J Invest Med"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0430","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jaci.2012.11.040","article-title":"Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis","volume":"131","author":"Zanotti","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0435","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/MOP.0b013e328355b248","article-title":"Childhood mastocytosis","volume":"24","author":"Torrelo","year":"2012","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0440","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1136\/jmg.2003.015156","article-title":"A germline mutation in KIT in familial diffuse cutaneous mastocytosis","volume":"41","author":"Tang","year":"2004","journal-title":"J Med Genet"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0445","first-page":"1160","article-title":"Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT","volume":"159","author":"Foster","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0450","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.exphem.2011.05.009","article-title":"Novel activating KIT-N822I mutation in familial cutaneous mastocytosis","volume":"39","author":"Wasag","year":"2011","journal-title":"Exp Hematol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0455","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/jdv.12182","article-title":"Absence of circulating mast cell precursors in paediatric mastocytosis: could it reflect a different pathophysiology between adults and children with mastocytosis?","volume":"28","author":"Georgin-Lavialle","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0460","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D","article-title":"Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa","volume":"92","author":"Beghini","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0465","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/pbc.22125","article-title":"Pediatric-onset mastocytosis. A long term clinical follow-up and correlation with bone marrow histopathology","volume":"53","author":"Uzzaman","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0470","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1468-3083.2011.04365.x","article-title":"Clinical aspects of paediatric mastocytosis: a review of 101 cases","volume":"27","author":"Lange","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0475","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/1042819021000037967","article-title":"Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c- Kit mutation ASP- 816-VAL","volume":"44","author":"Noack","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"Suppl","key":"10.1016\/j.critrevonc.2014.09.001_bib0480","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.jaci.2005.12.501","article-title":"Longitudinal disease progression in mastocytosis syndromes: a retrospective chart review","volume":"117","author":"Vogel","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0485","first-page":"2528","article-title":"Genetic evaluation of familial mastocytosis [abstract]","volume":"129","author":"Bursztejn","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2014.09.001_bib0490","doi-asserted-by":"crossref","first-page":"S348","DOI":"10.14309\/00000434-201010001-00962","article-title":"Gastrointestinal manifestations in cutaneous mastocytosis evolving into systemic mastocytosis","volume":"105","author":"Bhamidimarri","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0495","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-2133.1999.02814.x","article-title":"Lack of c-kit mutation in familial urticaria pigmentosa","volume":"140","author":"Rosbotham","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0500","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/archderm.1994.01690070131025","article-title":"Urticaria pigmentosa in monozygotic twins","volume":"130","author":"Offidani","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0505","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2340\/0001555575244","article-title":"Urticaria pigmentosa in identical male twins","volume":"75","author":"Pec","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0510","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1468-3083.2000.00018.x","article-title":"Familial mastocytosis associated with neurosensory deafness","volume":"14","author":"Trevisan","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0515","first-page":"320","article-title":"Pediatric cutaneous mastocytosis: a review of 180 patients","volume":"7","author":"Ben-Amitai","year":"2005","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0520","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1525-1578(10)60552-1","article-title":"C-kit mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation","volume":"7","author":"Yanagihori","year":"2005","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0525","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1525-1470.2011.01351.x","article-title":"Cutaneous mastocytosis in twins: multiple mastocytomas and urticaria pigmentosa in two pairs of monozygotic twins","volume":"28","author":"de la Sotta","year":"2011","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0530","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/ced.12225","article-title":"A new germline mutation in KIT associated with diffuse cutaneous mastocytosis in a Chinese family","volume":"39","author":"Wang","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0535","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/DAD.0b013e31826330bf","article-title":"Familial urticaria pigmentosa: report of a family and review of the role of KIT mutations","volume":"35","author":"Fett","year":"2013","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0540","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1046\/j.1365-2133.1999.02890.x","article-title":"Analysis of c-kit exon 11 and exon 17 of urticaria pigmentosa that occurred in monozygotic twin sisters","volume":"140","author":"Sato-Matsumura","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0545","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2014.09.001_bib0550","first-page":"519","article-title":"Next generation sequencing of 213 MDS patient samples identifies mutation profiles associated with response to hypomethylating agents and overall survival [abstract]","volume":"37","author":"Bejar","year":"2013","journal-title":"Leukemia Res"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2014.09.001_bib0555","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0145-2126(13)70258-3","article-title":"Splicing gene mutations in MDS and secondary AML: Clinical implications in the setting of allogeneic hematopoietic stem cell transplantation [abstract]","volume":"37","author":"Thol","year":"2013","journal-title":"Leukemia Res"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0560","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1182\/blood-2013-02-451757","article-title":"The myelodysplastic syndrome as a prototypical epigenetic disease","volume":"121","author":"Issa","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0565","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0570","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood-2013-01-451781","article-title":"Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia","volume":"121","author":"Abdel-Wahab","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0575","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nrd3823","article-title":"The spliceosome as a target of novel antitumour drugs","volume":"11","author":"Bonnal","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0580","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/blood-2012-05-378596","article-title":"Targeting oncogenic Ras signaling in hematologic malignancies","volume":"120","author":"Ward","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0585","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1365-2141.1997.d01-2042.x","article-title":"A new c-kit mutation in a case of aggressive mast cell disease","volume":"96","author":"Pignon","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0590","first-page":"225A","article-title":"Simultaneous JAK2 V617F and KIT D816V mutations in systemic mastocytosis","volume":"19","author":"Galderisi","year":"2006","journal-title":"Modern Pathology"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0595","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0600","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2141.2010.08536.x","article-title":"JAK2-positive myeloproliferative neoplasm co-existing with systemic mastocytosis","volume":"152","author":"Thachil","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0605","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaci.2012.04.013","article-title":"Mastocytosis Centre. Odense University Hospital (MastOUH). Adult-onset systemic mastocytosis in monozygotic twins with KIT D816V and JAK2 V617F mutations","volume":"130","author":"Broesby-Olsen","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0610","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.3324\/haematol.2013.090506","article-title":"SF3B1 mutations are infrequently found in non-Myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype","volume":"98","author":"Visconte","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0615","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2010.031690","article-title":"Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis","volume":"96","author":"Wilson","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0620","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1398-9995.2008.01827.x","article-title":"Interleukin-13 promoter gene polymorphism -1112C\/T is associated with the systemic form of mastocytosis","volume":"64","author":"Nedoszytko","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0625","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood.V98.3.880","article-title":"Association of the Q576R polymorphism in the interleukin-4 receptor alpha chain with indolent mastocytosis limited to the skin","volume":"98","author":"Daley","year":"2001","journal-title":"Blood"},{"issue":"Suppl 88","key":"10.1016\/j.critrevonc.2014.09.001_bib0630","first-page":"154","article-title":"Associations of TNF-alpha gene polymorphisms and mastocytosis. A study of the European Competence Network in Mastocytosis (ECNM) [abstract]","volume":"63","author":"Nedoszytko","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0635","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.leukres.2011.10.009","article-title":"Unique association of systemic mastocytosis and myeloid\/lymphoid neoplasm in blast crisis with abnormality of FGFR1 gene","volume":"36","author":"Mayeur-Rousse","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0640","first-page":"871","volume":"89","author":"Tefferi","year":"2004","journal-title":"FIP1L1- PDGFRA and c-kit D816V mutation- based clonality studies in systemic mast cell disease associated with eosinophilia Haematologica"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2014.09.001_bib0645","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000312134","article-title":"FIP1L1\/PDGFR alpha-associated systemic mastocytosis","volume":"152","author":"Yamada","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0650","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0655","doi-asserted-by":"crossref","first-page":"AB232","DOI":"10.1016\/j.jaci.2009.12.905","article-title":"Identification of TET2 mutations in subjects with systemic mastocytosis and hypereosinophilic syndrome","volume":"125","author":"Schroer","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0660","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.leukres.2006.03.006","article-title":"Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone","volume":"31","author":"Pullarkat","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0665","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.leukres.2013.08.010","article-title":"Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1","volume":"37","author":"Pullarkat","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0670","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0675","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/jid.2012.394","article-title":"A c-kit mutation in exon 18 in familial mastocytosis","volume":"133","author":"W\u00f6hrl","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0680","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0145-2126(02)00041-3","article-title":"Detection of c- kit point mutation Asp-816 \u2192 Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia","volume":"26","author":"Sotlar","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0685","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/10428190802140865","article-title":"The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells","volume":"49","author":"Ozer","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0690","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0609.2012.01761.x","article-title":"Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-kit tyrosine kinase inhibitor","volume":"89","author":"Georgin-Lavialle","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0695","first-page":"517546","article-title":"Mast cell leukaemia: c-kit mutations are not always positive","volume":"2012","author":"Joris","year":"2012","journal-title":"Case Report Hematol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0700","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1111\/ijlh.12147","article-title":"A case of de novo aleukemic mast cell leukemia without c-KIT mutations in exons 8 and 17","volume":"36","author":"Park","year":"2014","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0705","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1053\/j.gastro.2005.06.060","article-title":"Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis","volume":"129","author":"Hartmann","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0710","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1200\/JCO.2012.42.0133","article-title":"Rare germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis","volume":"31","author":"Speight","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0715","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1182\/blood.V122.21.5267.5267","article-title":"Familial mastocytosis: identification of KIT K509I mutation and its in vitro sensitivity to imatinib, dasatinib and PK412","volume":"122","author":"de Melo Campos","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0720","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A novel K5091 mutation of KIT identified in familial mastocytosis - in vitro and in vivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leukemia Res"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0725","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c- Kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2014.09.001_bib0730","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.jaci.2005.12.500","article-title":"Indolent systemic mastocytosis with germline D816V somatic c-kit mutation evolving to an acute myeloid leukemia","volume":"117","author":"Escribano","year":"2006","journal-title":"J Allery Clin Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0735","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jaci.2013.12.1090","article-title":"Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype","volume":"134","author":"Chan","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0740","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/leu.2011.354","article-title":"Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor \u03b2 chain and KIT V654A","volume":"26","author":"Spector","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.09.001_bib0745","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/1209","article-title":"Familial gastrointestinal stromal tumours with germline mutation of the KIT gene","volume":"19","author":"Nishida","year":"1998","journal-title":"Nat Genet"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842814001498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842814001498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T21:35:11Z","timestamp":1689543311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842814001498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":149,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1040842814001498"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2014.09.001","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}